{"nctId":"NCT01674712","briefTitle":"A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease","startDateStruct":{"date":"2012-06"},"conditions":["Dyslipidemia"],"count":575,"armGroups":[{"label":"Fenofibrate/simvastatin 145/20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Fixed Combination of Fenofibrate/simvastatin 145/20 mg"]},{"label":"Simvastatin 20 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Simvastatin 20 mg"]},{"label":"Fenofibrate 145 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fenofibrate 145 mg"]},{"label":"Fenofibrate/simvastatin 145/40 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Fixed Combination of Fenofibrate/simvastatin 145/40 mg"]},{"label":"Simvastatin 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Simvastatin 40 mg"]}],"interventions":[{"name":"Fixed Combination of Fenofibrate/simvastatin 145/20 mg","otherNames":[]},{"name":"Simvastatin 20 mg","otherNames":[]},{"name":"Fenofibrate 145 mg","otherNames":[]},{"name":"Fixed Combination of Fenofibrate/simvastatin 145/40 mg","otherNames":[]},{"name":"Simvastatin 40 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Either gender (tentatively 50 percent females to be included and if of childbearing potential she must agree to use medically acceptable methods of contraception from the time of signing the informed consent until 7 days following administration of the last treatment or dose of study medication). Accepted contraceptive methods are implants, injectables, combined oral contraceptives, intra-uterine device or sexual abstinence.\n2. between 18 (inclusive) and 80 years\n3. With mixed dyslipidemia with fasting lipid results of a blood sample taken at inclusion and after at least 3 months of any statin monotherapy (excluding simvastatin 80 mg, atorvastatin 40 mg and 80 mg, rosuvastatin 20 mg and 40 mg):\n\n   * TG higher than/equal to 1.71 mmol/L (higher than/equal to 150 mg/dL) and\n   * LDL-C higher or equal to 1.81 mmol/L (higher or equal 70 mg/dL) but smaller than/equal to 3.36 mmol/L (smaller than/equal to 130 mg/dL)\n4. High risk or very high risk based on known CardioVascular Disease (CVD) or type 2 diabetes or type 1 diabetes with microalbuminuria or a Systematic Coronary Risk Estimation (SCORE) chart risk â‰¥ 5percent\n5. Aspartate aminotransferase and/or alanine aminotransferase smaller than/equal to 2 times the Upper Normal of Limit (UNL)\n\nExclusion Criteria:\n\n1. Known hypersensitivity to fibrates or simvastatin or known photoallergic or phototoxic reactions under treatment with fibrates or ketoprofen or known allergic reactions caused by peanuts, peanuts or arachis oil or soy lecithin, or related products,\n2. Pregnant or lactating women,\n3. Unable or unwilling to comply with the protocol and the recommended diet,\n4. Likely to withdraw from the study before its completion,\n5. Having received an investigational drug or vaccine in the last 30 days before date of inclusion, or still participating in such a trial at Visit 1","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Change of TG (Triglyceride)","description":"Collection and measurement of blood samples.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.6","spread":"25.8"},{"groupId":"OG001","value":"10.7","spread":"48.8"},{"groupId":"OG002","value":"-27.3","spread":"35.9"},{"groupId":"OG003","value":"-2.9","spread":"34.3"},{"groupId":"OG004","value":"-21.6","spread":"34.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol)","description":"Collection and measurement of blood samples.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"16.8"},{"groupId":"OG001","value":"0.3","spread":"12.1"},{"groupId":"OG002","value":"8.8","spread":"16.5"},{"groupId":"OG003","value":"2.2","spread":"12.5"},{"groupId":"OG004","value":"7.6","spread":"15.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)","description":"Collection and measurement of blood samples.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"25.4"},{"groupId":"OG001","value":"-2.0","spread":"24.8"},{"groupId":"OG002","value":"-6.1","spread":"26.2"},{"groupId":"OG003","value":"-8.1","spread":"25.8"},{"groupId":"OG004","value":"30.3","spread":"35.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Non-HDL (High Density Lipoprotein)-C From Baseline","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Percentage of TC (Triglyceride) From Baseline","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Percentage of Apolipoprotein AI From Baseline","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Percentage of Apolipoprotein B From Baseline","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Percentage of High-sensitivity C-reactive Protein (hsCRP) From Baseline","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Percentage of Subjects Meeting Target Levels of Lipids (According to Very High or High Risk)","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Adverse Events","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Creatine Kinase (CK)","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Alanine Aminotransferase (ALT)","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Plasma Creatinine","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Total Bilirubin","description":"Collection and measurement of blood samples","classes":[]},{"type":"SECONDARY","title":"Cystatin C","description":"Collection and measurement of blood samples","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":111},"commonTop":["DIARRHOEA","NASOPHARYNGITIS","BLOOD CREATINE PHOSPHOKINASE INCREASED","GASTROENTERITIS","DYSPEPSIA"]}}}